DRonabinol Tratamento da AOS (DROSA)
Tratamento direcionado da apneia obstrutiva do sono com dronabinol: prova de conceito e ensaio clínico de fase II
This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Obstructive sleep apnea (OSA), is a serious respiratory disorder that involves repetitive cessation of breathing during sleep. It is estimated that 15-20 million people in the United States suffer from OSAS, which has been linked to increased risk for hypertension, heart failure, depression, and diabetes. The current standard of care for OSA, positive airway pressure (PAP), involves a mechanical device with low patient tolerance and adherence. Upper airway surgical approaches are also an option but are invasive and often unsuccessful. Effective drug treatments for OSA remain to be identified.
This study will enroll up to 120 Veterans so that 45 Veterans may complete the two-week open-label Dronabinol treatment trials. The results of the study will be used to develop a prediction model for OSA severity reduction after 2-week Dronabinol treatment vs. pretreatment AHI. Participants clinical (age, sex, body mass index, comorbidity) and pretreatment polysomnographic characteristics (sleep architecture, respiratory disturbance, and endotypes; loop-gain, arousal threshold, upper airway collapsibility and compensation) will be used to develop a prediction model for improvement of OSA with Dronabinol treatment. This prediction model will be used for a randomized clinical trial after the completion of this trial.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Karen M Lenehan
- Número de telefone: (312) 569-6343
- E-mail: Karen.Lenehan@va.gov
Estude backup de contato
- Nome: Bharati Prasad, MD
- Número de telefone: (312) 996-8433
- E-mail: bharati.prasad@va.gov
Locais de estudo
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Recrutamento
- Jesse Brown VA Medical Center, Chicago, IL
-
Contato:
- Howard S Gordon, MD BS
- Número de telefone: (312) 569-7331
- E-mail: howard.gordon2@va.gov
-
Contato:
- Karen M Lenehan
- Número de telefone: (312) 569-6343
- E-mail: Karen.Lenehan@va.gov
-
Investigador principal:
- Bharati Prasad, MD
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
1. AHI 15-50 per hour on pre-treatment polysomnography
Exclusion Criteria:
-
Positive Airway Pressure (PAP) treatment of obstructive sleep apnea (OSA): use > 4 hours per day for 30% of days within 3 months of enrollment. PAP use will be determined from device download data
-
Hypoglossal nerve stimulator (HNS) or oral appliance device treatment with use > 4 hours per day for 30% of days within 3 months of enrollment. HNS use will be determined by device download and oral appliance use by self-report
-
History of upper airway surgery for OSA (except adenotonsillectomy)
-
Central or mixed apneas >25% of respiratory events on diagnostic polysomnography
-
Arterial oxygen saturation < 75% for > 5% sleep time on pretreatment polysomnography
-
Body mass index > 45 kilograms per square meter (kg/m2)
-
If post-bariatric surgery, weight must be stable ±5% (per electronic medical records) for at least 6 months before the first dose of the study drug
-
Active enrollment in a weight loss program
-
Shiftwork within 3 months of enrollment
-
High-risk occupation: commercial driver and pilot
-
Motor vehicle accident or near-miss incident within 1 year of enrollment
-
Current drug or habitual alcohol use or positive urine drug screen
-
Comorbid medical and psychiatric disorders:
- Primary sleep disorders: e.g., narcolepsy, restless legs syndrome
- Uncontrolled mood disorder or a diagnosis of schizophrenia
- Initiation of new antidepressant or antipsychotic medication within 3 months
- Identified as high-risk for suicide in electronic health records
- Uncontrolled medical disorders (coronary heart disease, arrhythmia, congestive heart failure, chronic obstructive pulmonary disease, chronic hypoxemic or hypercapnic respiratory failure, stroke within 6 months of enrollment, chronic liver or kidney disease, autoimmune disorders)
-
Use of sedative-hypnotic medications within 30 days of enrollment
-
Complete blood count or liver function test values more than 1.5 times the upper limit of normal
-
Pregnancy
-
Allergy to cannabinoids or sesame oil
-
Average weekly alcohol consumption of more than 10 servings
-
Participation in other investigational protocols within 30 days of enrollment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Single group
Open label Dronabinol treatment for two weeks. |
Open label Dronabinol treatment for two weeks.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Apnea Hypopnea Index (AHI)
Prazo: 2 weeks
|
The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
T<90
Prazo: 2 weeks
|
The change in time below 90% oxygen saturation (T<90) after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Psychomotor Vigilance Test (PVT)
Prazo: 2 weeks
|
The change in Lapses on Psychomotor Vigilance Test (PVT) after two weeks of Dronabinol treatment will be determined from before and after treatment PVT using a 10 minute protocol. |
2 weeks
|
|
24-hour Mean Arterial Blood Pressure (BP)
Prazo: 2 weeks
|
The change in 24- hour mean arterial blood pressure after two weeks of Dronabinol treatment will be determined from before and after treatment 24-hiur ambulatory BP recording. |
2 weeks
|
|
Sleep Efficiency
Prazo: 2 weeks
|
The change in sleep efficiency after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Rapid Eye Movement (REM) Sleep
Prazo: 2 weeks
|
The change in REM sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Slow Wave Sleep
Prazo: 2 weeks
|
The change in slow wave sleep after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms. |
2 weeks
|
|
Treatment Satisfaction Questionnaire for Medication (TSQM)
Prazo: 2 weeks
|
Patient reported treatment satisfaction. TSQM scores have a range of 0 to 100, with higher scores indicating higher satisfaction. |
2 weeks
|
|
Epworth Sleepiness Scale (ESS)
Prazo: 2 weeks
|
The change in Epworth Sleepiness Scale (ESS) will be measured after two weeks of Dronabinol treatment. ESS scores have a range of 0 to 24, with higher scores indicating greater sleepiness. |
2 weeks
|
|
Functional Outcomes of Sleep Questionnaire (FOSQ)
Prazo: 2 weeks
|
The change in Functional Outcomes of Sleep Questionnaire (FOSQ) will be measured after two weeks of Dronabinol treatment. FOSQ score ranges from 5-20, with higher scores indicating better functional status. |
2 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
Prazo: 2 weeks
|
The change in Pittsburgh Sleep Quality Index (PSQI) will be measured after two weeks of Dronabinol treatment. The PSQI score ranges from 0 to 21. Higher scores indicate poorer sleep quality. |
2 weeks
|
|
Insomnia Severity Index (ISI)
Prazo: 2 weeks
|
The change in Insomnia Severity Index (ISI) will be measured after two weeks of Dronabinol treatment. ISI ranges from 0 to 28, with higher scores indicating greater sleep disturbance. |
2 weeks
|
|
Post-Traumatic Stress Disorder; PTSD checklist (PCL-5)
Prazo: 2 weeks
|
The change in Post-Traumatic Stress Disorder; PTSD checklist (PCL-5) will be measured after two weeks of Dronabinol treatment. PCL-5 scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. |
2 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Bharati Prasad, MD, Jesse Brown VA Medical Center, Chicago, IL
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- PULM-011-23F
- 5I01CX002632-02 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .